Ami B Patel
Overview
Explore the profile of Ami B Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li P, Alnoor F, Xie W, Williams M, Feusier J, Ding Y, et al.
Leukemia
. 2024 Nov;
39(1):248-256.
PMID: 39516371
No abstract available.
2.
Zhukovsky S, Rets A, Braaten T, Patel A
EJHaem
. 2024 Oct;
5(5):981-986.
PMID: 39415928
Introduction: VEXAS syndrome is a rare condition characterized by somatic mutations in the ubiquitin-like modifier activating enzyme 1 () gene and a constellation of clinical/morphologic findings, including the presence of...
3.
Vardell V, Ose J, Rets A, Tantravahi S, Patel A
Clin Lymphoma Myeloma Leuk
. 2024 Aug;
24(12):843-851.
PMID: 39179449
Background: Myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN) are rare blood cancers characterized by concomitant myeloid hyperplasia and dysplasia. These heterogenous disorders include chronic myelomonocytic leukemia (CMML) and atypical chronic myeloid leukemia (aCML)....
4.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Kaur A, Rojek A, Symes E, Nawas M, Patel A, Patel J, et al.
Blood Cancer J
. 2024 Jun;
14(1):99.
PMID: 38890297
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to...
5.
Patel A, Masarova L, Mesa R, Hobbs G, Pemmaraju N
Leuk Lymphoma
. 2024 Jun;
65(11):1552-1564.
PMID: 38871488
There has been remarkable progress in the development of novel therapeutic approaches for patients with polycythemia vera (PV). Historically, therapy goals in PV were to mitigate thrombotic risks and control...
6.
Gillis N, Dickey B, Colin-Leitzinger C, Tang Y, Putney R, Mesa T, et al.
J Infect Dis
. 2024 Apr;
230(3):680-688.
PMID: 38657098
Background: Cancer-related deaths for people with human immunodeficiency virus (PWH) are increasing due to longer life expectancies and disparately poor cancer-related outcomes. We hypothesize that advanced biological aging contributes to...
7.
8.
Krah N, Miotke L, Li P, Patel J, Bowen A, Pomicter A, et al.
J Natl Compr Canc Netw
. 2023 Dec;
21(12):1218-1223.
PMID: 38081125
A 66-year-old male presented with hypereosinophilia, thrombocytosis, extensive thrombosis refractory to direct oral anticoagulant therapy, and evidence of end-organ damage, including rash, splenic infarcts, and pulmonary infiltrates. Bone marrow biopsy...
9.
Dickey B, Putney R, Suneja G, Kresovich J, Spivak A, Patel A, et al.
AIDS
. 2023 Jul;
37(13):2049-2057.
PMID: 37467055
Objective: People with HIV (PWH) are living longer and experiencing higher numbers of non-AIDS-defining cancers (NADC). Epigenetic aging biomarkers have been linked to cancer risk, and cancer is now a...
10.
Parzen-Johnson S, Sun S, Patel A, Scardina T, Shah S, Patel S
JAMA Netw Open
. 2022 Dec;
5(12):e2248671.
PMID: 36576739
Importance: Minoritized groups are less likely to receive COVID-19 therapeutics, but few studies have identified potential methods to reduce disparities. Objective: To determine whether screening plus outreach, when compared with...